Expression of miR-155 and miR-126 in situ in cutaneous T-cell lymphoma
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Expression of miR-155 and miR-126 in situ in cutaneous T-cell lymphoma. / Kopp, Katharina L; Ralfkiaer, Ulrik; Nielsen, Boye S; Gniadecki, Robert; Andersen, Anders Woetmann; Ødum, Niels; Ralfkiaer, Elisabeth.
In: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, Vol. 121, No. 11, 11.2013, p. 1020-4.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Expression of miR-155 and miR-126 in situ in cutaneous T-cell lymphoma
AU - Kopp, Katharina L
AU - Ralfkiaer, Ulrik
AU - Nielsen, Boye S
AU - Gniadecki, Robert
AU - Andersen, Anders Woetmann
AU - Ødum, Niels
AU - Ralfkiaer, Elisabeth
N1 - © 2013 APMIS. Published by John Wiley & Sons Ltd.
PY - 2013/11
Y1 - 2013/11
N2 - Recently, miR-155 has been implicated in cutaneous T-cell lymphoma (CTCL). Thus, elevated levels of miR-155 were observed in skin lesions from CTCL patients as judged from qPCR and micro-array analysis and aberrant, high miR-155 expression was associated with severe disease. Moreover, miR-155 promoted proliferation of malignant T cells in vitro. Little is, however, known about which cell types express miR-155 in vivo in CTCL skin lesions. Here, we study miR-155 expression using in situ hybridization (ISH) with a miR-155 probe, a negative control (scrambled), and a miR-126 probe as a positive control in nine patients with mycosis fungoides, the most frequent subtype of CTCL. We provide evidence that both malignant and non-malignant T cells stain weakly to moderately positive with the miR-155 probe, but generally negative with the miR-126 and negative control probes. Reversely, endothelial cells stain positive for miR-126 and negative for miR-155 and the control probe. Solitary T cells with a malignant morphology display brighter staining with the miR-155 probe. Taken together, our findings suggest that both malignant and non-malignant T cells express miR-155 in situ in CTCL. Moreover, they indicate heterogeneity in miR-155 expression among malignant T cells.
AB - Recently, miR-155 has been implicated in cutaneous T-cell lymphoma (CTCL). Thus, elevated levels of miR-155 were observed in skin lesions from CTCL patients as judged from qPCR and micro-array analysis and aberrant, high miR-155 expression was associated with severe disease. Moreover, miR-155 promoted proliferation of malignant T cells in vitro. Little is, however, known about which cell types express miR-155 in vivo in CTCL skin lesions. Here, we study miR-155 expression using in situ hybridization (ISH) with a miR-155 probe, a negative control (scrambled), and a miR-126 probe as a positive control in nine patients with mycosis fungoides, the most frequent subtype of CTCL. We provide evidence that both malignant and non-malignant T cells stain weakly to moderately positive with the miR-155 probe, but generally negative with the miR-126 and negative control probes. Reversely, endothelial cells stain positive for miR-126 and negative for miR-155 and the control probe. Solitary T cells with a malignant morphology display brighter staining with the miR-155 probe. Taken together, our findings suggest that both malignant and non-malignant T cells express miR-155 in situ in CTCL. Moreover, they indicate heterogeneity in miR-155 expression among malignant T cells.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Female
KW - Humans
KW - In Situ Hybridization
KW - Lymphoma, T-Cell, Cutaneous
KW - Male
KW - MicroRNAs
KW - Middle Aged
KW - Skin Neoplasms
U2 - 10.1111/apm.12162
DO - 10.1111/apm.12162
M3 - Journal article
C2 - 24033365
VL - 121
SP - 1020
EP - 1024
JO - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica
JF - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica
SN - 0903-4641
IS - 11
ER -
ID: 117551720